The Federal Circuit’s March 21, 2025 decision in Maquet Cardiovascular LLC v. Abiomed Inc. et al. (No. 2023-2045) and the recent Patent Trial and Appeal Board (PTAB) Delegated Rehearing Panel decision in SynAffix B.V. v....more
6/6/2025
/ CAFC ,
Claim Construction ,
Disclaimers ,
Inter Partes Review (IPR) Proceeding ,
Life Sciences ,
Patent Applications ,
Patent Litigation ,
Patent Prosecution History ,
Patent Trial and Appeal Board ,
Pharmaceutical Industry ,
Prior Art
In Regeneron Pharms., Inc. v. Mylan Pharms. Inc., the Federal Circuit recently held that biosimilar pharmaceutical companies that filed abbreviated Biologics License Applications (aBLAs) and planned to make a single sale to a...more